Interaction of cyclosporine with phenobarbital in cats: a preliminary study

Yuki HOSHINO\textsuperscript{1)}, Takanori INDEN\textsuperscript{1)}, Riko OTAKA\textsuperscript{1)}, Daisuke FUKUI\textsuperscript{1)}, Hiroshi SATOH\textsuperscript{2)} and Masaaki KATAYAMA\textsuperscript{1)*}

\textsuperscript{1)}Division of Small Animal Surgery, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, 3-18-8 Ueda, Morioka, Iwate 020-8550, Japan
\textsuperscript{2)}Division of Veterinary Pharmacology and Toxicology, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, 3-18-8 Ueda, Morioka, Iwate 020-8550, Japan

\textbf{ABSTRACT.} Phenobarbital (PB) decreases the cyclosporine (CsA) blood level in humans. However, the interaction of PB with CsA has not been reported in cats. This study investigated the effects of multiple doses of PB on the pharmacokinetics of CsA in three healthy cats. The treatments included oral CsA 5 mg/kg alone and oral CsA 5 mg/kg plus PB 5 mg/kg for 4 weeks. Co-administration of PB with CsA resulted in significant decreases in the oral bioavailability of CsA though both the first pass and elimination phases. These preliminary results suggest that oral administration of multiple doses of PB increases the required CsA dosage in CsA-based immunosuppressive therapy in cats.

\textbf{KEY WORDS:} cat, cyclosporine, pharmacokinetics, phenobarbital

Cyclosporine (CsA) is currently the core immunosuppressive drug for the prevention of allograft rejection after renal transplantation in cats [9]. In humans, CsA is a substrate of cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp) [6, 10, 23]. CYP is the most important enzyme family for drug metabolism in humans and other species. P-gp belongs to a subfamily of ATP-binding cassette transporters, and is involved in CsA excretion and acts as a drug efflux pump that actively transports CsA into the intestinal lumen [6, 12]. Therefore, the bioavailability of CsA could be affected by the co-administration of substrates of CYP and/or P-gp. Phenobarbital (PB) is the barbiturate used most commonly to treat seizures and epilepsy in dogs and cats [2]. PB is a strong CYP3A and P-gp inducer and is metabolized by CYP2C in hepatic microsomes in humans [20]. PB decreases blood CsA concentrations by inducing CYP and P-gp in humans [18]. In feline renal transplantation, an abrupt decline in blood CsA levels should be avoided because it will cause acute rejection. To our knowledge, however, there are no reports on the interaction of CsA with PB in cats. Therefore, this study evaluated the effects of PB on blood CsA levels in cats. We investigated the effects of administering multiple doses of oral PB on the pharmacokinetics of CsA in healthy cats. This study was classified as preliminary because of a small number of animals used.

Three healthy male cats were used in this study. Their weights ranged from 5.8 to 6.8 kg and their ages from 6 to 7 years old. Before this study, all cats were confirmed to be healthy based on a physical examination, complete blood count, biochemical profile, and urinalysis. Each cat underwent two treatments (A and B). In a clinical setting, CsA is administered a dosage of 3 to 5 mg/kg twice daily for renal transplantation in cats [5]. Therefore, the dose of CsA (Fine granules 17% [Mylan], Mylan, Tokyo, Japan) was adjusted to 5 mg/kg. The PB dose was about 5 mg/kg [mean dose 4.8 ± 0.4 (range 4.4–5.8) mg/kg, Phenovar® Tablets 30 mg, Fujinaga, Tokyo, Japan], which is reported to be sufficient for seizure control in cats [1, 4].

For treatment A, the cats received oral CsA alone. For treatment B, the cats were given 5 mg/kg PB once daily for 4 weeks and CsA 1 hr after the PB dose on day 28. The washout time between treatments was at least 1 month. The cats had access to water \textit{ad libitum} throughout the study. A complete blood count, serum biochemical analysis, and urinalysis were repeated at the end of the study to detect any adverse effects of the drugs. This study was approved by the Iwate University Animal Care and Use Committee (A201337).

Two days before CsA administration, all three cats underwent brief anesthesia to place an indwelling 20-gauge 15-cm catheter (SMAC plus; Covidien, Shizuoka, Japan) in the right jugular vein. The catheter was maintained with daily flushing with heparinized saline until the experiment started. Whole blood samples were collected in dipotassium EDTA tubes through the catheter 0.5, 1, 2, 4, 6, 10, 12, and 24 hr after CsA administration. The catheter was flushed with heparinized saline after each sample collection. Then, the catheter was removed 2 days after the blood sampling. The blood samples were stored at $-80^\circ C$.
The maximum blood concentration (Cmax) and its corresponding time (tmax) were determined for each cat by plotting the blood CsA concentration versus time profile. The area under the curve from 0 to 24 hr (AUC0–24) after CsA administration was calculated by the linear trapezoidal method. The terminal elimination rate constant (k) was calculated by linear least-squares regression analysis using the last three measurement points in the log-linear terminal phase. The t1/2 was estimated to be 0.693/k. The area under the first moment curve from 0 to 24 hr (AUMC0–24) after CsA administration was also calculated by the linear trapezoidal method. The mean residence time (MRT) was calculated as AUMC0–24/AUC0–24. Differences in the pharmacokinetic parameters between each treatment were analyzed using the paired t-test and were regarded as statistically significant at P<0.05. Each value is shown as the mean ± SE.

Figure 1 shows the mean CsA blood concentration–time curves of the three cats. The Cmax of the cats given repeated PB was 531.0 ± 126.0 ng/ml, approximately half the value in the cats treated with CsA alone (1,266.0 ± 183.0 ng/ml); this difference was significant (P<0.05). The AUC0–24 was 6,153.2 ± 2,676.9 ng/ml for treatment B and 14,026.7 ± 3,096.0 ng/ml for treatment A, and t1/2 was 7.4 ± 0.8 and 14.8 ± 1.0 hr, respectively. Both values were significantly lower with treatment B (P<0.05). The tmax was 4.7 ± 0.8 hr with treatment A and 6.0 ± 1.2 hr with treatment B, and did not differ significantly. MRT0–24 was 9.6 ± 0.1 hr with treatment A and 9.9 ± 0.7 hr with treatment B, and did not differ significantly. Table 1 lists the pharmacokinetic parameters for the three cats for each treatment.

In humans, the metabolism of CsA is mediated primarily by CYP, specifically CYP3A1, in the liver and small intestine [6, 23]. PB is a CYP enzyme inducer [20] and can reduce blood CsA concentrations by inducing CYP enzymes, especially CYP3A [16, 22]. CYP3A has various isoforms and its tissue distribution is species dependent. In cats, two isoforms of CYP3A have been identified: CYP3A131 and CYP3A132 [7]. Both isoforms share the highest homology with canine CYP3A12, which is associated with CsA metabolism in dogs [13]. CYP3A131 transcript expression predominates in the liver and small intestine, with some expression in the brain and lungs [7]. Beusekom et al. [21] reported that hepatic microsomes in cats showed lower CYP3A activity than in dogs and humans. In feline renal transplant patients, ketoconazole reduces the dosage of CsA to approximately 60% of the total amount required to maintain the therapeutic CsA blood levels [14], which suggests that CsA metabolism is mediated partially by CYP3A in cats, as in humans. In cats, CYP3A also affects CsA metabolism, as in dogs and humans, despite its lower activity. Further investigation of the details of the effects of PB on CYP3A in cats is needed.

It has recently been shown that P-gp is involved in the pharmacokinetics of CsA [19, 24]. P-gp is a drug efflux pump that actively transports CsA into the intestinal lumen [6, 12], and CYP3A and P-gp have many common substrates [3]. In cats, P-gp was studied in vitro in feline lymphoma cells; the results suggested that the basic structure of the feline ortholog and its role in multidrug resistance were essentially the same as in other species [17]. To our knowledge, there is no study regarding whether PB can promote P-gp expression in intestine or liver. However, the long-term administration of PB and repeated seizures were reported to promote overexpression of P-gp in rat brain tissue [8]. These findings suggest that PB activates both the catalytic activity of CYP3A and the efflux function of P-gp, which may influence the pharmacokinetics of CsA in cats.

Based on our results, the administration of multiple oral doses of PB could decrease the blood concentration and AUC0–24 of CsA compared with CsA alone. In addition, t1/2 differed statistically between CsA alone and CsA with PB. This implies that the administration of multiple doses of PB could decrease CsA blood level in cats, via both metabolism (including the first pass) and

| Parameters | Treatment A (CsA alone) | Treatment B (CsA+PB) |
|------------|------------------------|----------------------|
| AUC0–24 (ng•hr/ml) | 14,026.7 ± 3,096.0 | 6,153.2 ± 2,676.9<sup>a</sup> |
| Cmax (ng/ml) | 1,266.0 ± 183.3 | 531.0 ± 126.0<sup>b</sup> |
| tmax (hr) | 4.7 ± 0.8 | 6.0 ± 1.2 |
| t1/2 (hr) | 14.8 ± 1.0 | 7.4 ± 0.8<sup>a</sup> |
| AUMC0–24 (ng•hr<sup>2</sup>/ml) | 135,559.4 ± 31,065.2 | 62,463.5 ± 22,090.6 |
| MRT0–24 (hr) | 9.6 ± 0.1 | 9.9 ± 0.7 |

Values are presented as means ± SE. Treatment A: CsA alone. Treatment B: CsA + multiple doses of PB. a) Statistically different from treatment group A (P<0.05).
the elimination phase in the pharmacokinetics of CsA, which is likely associated with CYP3A and P-gp activity.

Prevention of acute graft rejection correlates more strongly with AUC than trough level of cyclosporine in human solid organ transplant patients [11, 15]. Although monitoring of CsA trough level rather than AUC has been used in clinical feline renal transplantation, further study regarding relationship between AUC monitoring and clinical outcome of feline renal transplantation may be investigated in the future.

In conclusion, these preliminary findings show that PB significantly decreases the blood level of CsA in healthy cats and suggest that the co-administration of CsA with multiple oral doses of PB may require adjustment of the CsA dosage to prevent acute allograft rejection. A larger prospective study should explore the effects of PB on the CsA blood levels in cats.

REFERENCES

1. Cochrane, S. M., Parent, J. M., Black, W. D., Allen, D. G. and Lumsden, J. H. 1990. Pharmacokinetics of phenobarbital in the cat following multiple oral administration. Can. J. Vet. Res. 54: 309–312. [Medline] [CrossRef]

2. Delamaide Gasper, J. A., Barnes Heller, H. L., Robertson, M. and Trepanier, L. A. 2015. Therapeutic serum phenobarbital concentrations obtained using chronic transdermal administration of phenobarbital in healthy cats. J. Feline Med. Surg. 17: 359–363. [Medline] [CrossRef]

3. Eagling, V. A., Profit, L. and Back, D. J. 1999. Inhibition of the P3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48: 543–552. [Medline] [CrossRef]

4. Finnerty, K. E., Barnes Heller, H. L., Mercier, M. N., Giovanelia, C. J., Lau, V. W. and Rylander, H. 2014. Evaluation of therapeutic phenobarbital concentrations and application of a classification system for seizures in cats: 30 cases (2004–2013). J. Am. Vet. Med. Assoc. 244: 195–199. [Medline] [CrossRef]

5. Gregory, C. and Bernsteen, L. 2003. Organ transplantation in clinical veterinary practice. pp.112–136. In: Textbook of Small Animal Surgery, 3rd ed. (Slatter, D. ed.), Saunders, Philadelphia.

6. Hebert, M. F. 1997. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Deliv. Rev. 27: 201–214. [Medline] [CrossRef]

7. Honda, K., Komatsu, T., Koyama, F., Kubota, A., Kawakami, K., Asakura, H., Uno, Y., Kitazawa, T., Hiraga, T. and Teraoka, H. 2011. Expression of two novel cytochrome P450 3A131 and 3A132 in liver and small intestine of domestic cats. J. Vet. Med. Sci. 73: 1489–1492. [Medline] [CrossRef]

8. Jing, X., Liu, X., Wen, T., Xie, S., Yao, D., Liu, X., Wang, G. and Xie, L. 2010. Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br. J. Pharmacol. 159: 1511–1522. [Medline] [CrossRef]

9. Katayama, M. and McAnulty, J. 2002. Renal transplantation in cats: techniques, complications, and immunosuppression. Compd. Contin. Educ. Pract. Vet. 24: 874–882.

10. Kolars, J. C., Awni, W. M., Merion, R. M. and Watkins, P. B. 1991. First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488–1490.

11. Levy, G., Thervet, E., Lake, J., Uchida K., Consensus on Neoral C2: Expert Review in Transplantation (CONCERT) Group. 2002. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 73 Suppl: S12–S18. [Medline] [CrossRef]

12. Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H. L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z. and Watkins, P. B. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62: 248–260. [Medline] [CrossRef]

13. Martinez, M. N., Antonovic, L., Court, M., Dacasto, M., Fink-Gremmels, J., Kukanich, B., Locuson, C., Mealey, K., Myers, M. J. and Trepanier, L. 2013. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab. Rev. 45: 218–230. [Medline] [CrossRef]

14. McAnulty, J. F. and Lensmeyer, G. L. 1999. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet. Surg. 28: 448–455. [Medline] [CrossRef]

15. Nashan, B., Cole, E., Levy, G. and Thervet, E. 2002. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation 73 Suppl: S3–S11. [Medline] [CrossRef]

16. Nishikawa, T., Ikegami, M., Izumitani, M., Ishii, T., Uemura, T., Kunikata, S., Kanda, H., Matsuura, T., Akiyama, T. and Kurita, T. 1999. Interaction between phenobarbital and ciclosporin following renal transplantation: a case report. Hinyokika Kiyo 36: 447–450 (in Japanese). [Medline]

17. Okai, Y., Nakamura, N., Matsushiro, H., Kato, H., Setoguchi, A., Yazawa, M., Okuda, M., Watari, T., Hasegawa, A. and Tsujimoto, H. 2000. Molecular analysis of multidrug resistance in feline lymphoma cells. Am. J. Vet. Res. 61: 1122–1127. [Medline] [CrossRef]

18. Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G. and Maurel, P. 1990. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18: 595–606. [Medline] [CrossRef]

19. Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O. and Serabjit-Singh, C. S. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299: 620–628. [Medline] [CrossRef]

20. Raucy, J. L., Mueller, L., Duam, K., Allen, S. W., Strom, S. and Lasker, J. M. 2002. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther. 302: 475–482. [Medline] [CrossRef]

21. van Beusekom, C. D., Schipper, L. and Fink-Gremmels, J. 2010. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J. Vet. Pharmacol. Ther. 33: 519–527. [Medline] [CrossRef]

22. Venkataraman, R., Burckart, G. J., Ptachcinski, R. J., Esquivel, C. and Makowka, L. 1987. Interaction between cyclosporine and phenobarbital. J. Pharm. Sci. 76: 101. [Medline] [CrossRef]

23. Whalen, R. D., Tata, P. N., Burckart, G. J. and Venkataraman, R. 1999. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 29: 3–9. [Medline] [CrossRef]

24. Yu, D. K. 1999. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 39: 1203–1211. [Medline] [CrossRef]